falsefalse

Unpacking Key Data in Chronic Myeloid Leukemia After ASH 2024 - Episode 2

Factors That Influence Treatment Decisions in Later-Line CML

,

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Current Time 0:00
Duration 2:13
Loaded: 0%
Stream Type LIVE
Remaining Time 2:13
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML
Now Viewing
EP. 2: Factors That Influence Treatment Decisions in Later-Line CML
EP. 3: 5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial
EP. 4: Emerging Mutation Analysis from the OPTIC Trial
EP. 5: Dosing Strategies for Ponatinib in CML and ALL
EP. 6: The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL
EP. 7: Selecting a TKI in Subsequent Lines of Therapy in CML
EP. 8: Highlighting Key CML/ALL Data Presented at ASH 2024

Related Content:

Unpacking Key Data in Chronic Myeloid Leukemia After ASH 2024Moffitt Cancer CenterMayo ClinicHematologic OncologyOncLive News Network®
PROs, Gene Expression Vary Among Patients With AML Undergoing Induction Chemo
Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration
Dr Andorsky on Molecular Responses With Second-Line Asciminib in CP-CML
x